Study population
Patients implanted with the Micra Transcatheter Pacing System (Medtronic, Minneapolis, MN, USA), from 9 major tertiary European LPM implanting centers, between September 2015 and August 2019 (4 years), and followed in the Micra Transcatheter Pacing System Post-Approval Registry (NCT02536118) were retrospectively screened.
Inclusion criteria were: patients with an indication of prolonged cardiac pacing, who underwent an LPM implantation during the hospitalization in an ICU; and the presence of at least one of the following: ≥1 supracaval central venous line (including hemodialysis catheter), or a ventilation tube, or intravenous antibiotic therapy for ongoing sepsis or bacteremia. Exclusion criteria were: previous implantation of a pacemaker. This study was conducted in accordance with the amended Declaration of Helsinki, and written informed consent was obtained from all patients or their substitute decision-makers.
Data on clinical characteristics of patients, especially comorbidities, LPM implantation procedure, duration of hospitalization were collected. Patients had regular cardiovascular consultation including LPM interrogation of electrical parameters (≥1 per year).